Evaluation of Dalbavancin and Oritavancin as Cost-Effective Treatments of Acute Bacterial Skin and Skin Structure Infections in Hospitalized Patients

摘要

Background Acute bacterial skin and skin structure infections (ABSSSI) are a challenging medical problem associated with high health care costs. Dalbavancin and oritavancin are approved for treatment of ABSSSI and, due to their long half-life, are dosed as a one-time infusion. These agents may make it possible to allow for earlier discharge and reduce health care costs without compromising efficacy.